Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...

Pharmacokinetic Models: Comparison and Selection Criterion

Pharmacokinetic Models: Comparison and Selection Criterion

Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.

Pharmacodynamic Models: Direct Effect Model and Indirect Response Model

Pharmacodynamic Models: Direct Effect Model and Indirect Response Model

Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...

Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model

Pharmacodynamic Models: Link Model and Systems Pharmacodynamic Model

The link model is a fundamental pharmacokinetic-pharmacodynamic (PK–PD) approach to account for delayed drug responses when the observed effect does not immediately correlate with the drug's plasma concentration peak. This delay is mathematically addressed by introducing an effect compartment concentration, Ce, which is kinetically linked to the plasma concentration, Cp, via a first-order rate constant, ke0. The linkage allows for a more accurate prediction of drug effects over time. A...

Pharmacokinetic–Pharmacodynamic Relationship: Problems

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Population Pharmacokinetic Modelling of Apixaban in End-Stage Kidney Disease Patients with Atrial Fibrillation Receiving Haemodialysis.

Clinical pharmacokinetics·2025

Same author

SCF-SKP2 E3 ubiquitin ligase links mTORC1/ER stress/ISR with YAP activation in murine renal cystogenesis.

The Journal of clinical investigation·2022

Same author

In Situ Characterization of the Protein Corona of Nanoparticles In Vitro and In Vivo.

Advanced materials (Deerfield Beach, Fla.)·2022

Same author

Distinct transcriptomic profile of small arteries of hypertensive patients with chronic kidney disease identified miR-338-3p targeting GPX3 and PTPRS.

Journal of hypertension·2022

Same author

Tailoring PEGylated nanoparticle surface modulates inflammatory response in vascular endothelial cells.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2022

Same author

Scratching the Surface of the Protein Corona: Challenging Measurements and Controversies.

ACS nano·2022

Search research articles

Related Experiment Video

Updated: May 4, 2026

Modeling Fast-scan Cyclic Voltammetry Data from Electrically Stimulated Dopamine Neurotransmission Data Using QNsim1.0

Modeling Fast-scan Cyclic Voltammetry Data from Electrically Stimulated Dopamine Neurotransmission Data Using QNsim1.0

Published on: June 5, 2017

Artificial neural network modeling for drug dialyzability prediction.

Kahina Daheb, Mark L Lipman, Patrice Hildgen

Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques

|January 8, 2014

Summary

This study developed an artificial neural network (ANN) model to predict drug removal during dialysis. The ANN model accurately predicts drug clearance (CLD) using drug properties and dialysis conditions, offering a valuable tool for estimating drug removal.

Related Experiment Videos

Last Updated: May 4, 2026

Modeling Fast-scan Cyclic Voltammetry Data from Electrically Stimulated Dopamine Neurotransmission Data Using QNsim1.0

Modeling Fast-scan Cyclic Voltammetry Data from Electrically Stimulated Dopamine Neurotransmission Data Using QNsim1.0

Published on: June 5, 2017

Area of Science:

Pharmacokinetics and Drug Metabolism
Biomedical Engineering
Computational Chemistry

Background:

Accurate prediction of drug removal during dialysis is crucial for optimizing patient treatment.
Traditional experimental methods for determining drug clearance (CLD) are time-consuming and not feasible for all drugs.

Purpose of the Study:

To develop an artificial neural network (ANN) model for predicting drug removal during dialysis.
To utilize drug properties and dialysis conditions as input parameters for the ANN model.

Main Methods:

In vitro dialysis experiments were conducted using nine antihypertensive drugs.
Drug concentrations were quantified using HPLC or LC/MS/MS.
Artificial neural networks were constructed using Neurosolutions software to predict CLD based on molecular weight, logD, plasma protein binding, and ultrafiltration rate (UFR).

Main Results:

The addition of bovine serum albumin (BSA) significantly decreased CLD for carvedilol and labetalol.
Ultrafiltration rate (UFR) did not significantly impact CLD.
The best-performing ANN model, a Jordan and Elman network, demonstrated stable learning and good predictive accuracy (MSEtesting = 129).

Conclusions:

An effective ANN model was developed to predict drug removal during dialysis.
ANNs offer a promising alternative to experimental determination for predicting drug CLD, especially given the vast number of existing drugs.